☰
The fund would reportedly contribute toward disruptive scientific developments across a spate of therapeutic areas such as immunology, oncology, and neurosciences. ...
Read More >>The antibody, called as MTAU9937A, RO7105705, is also being assessed by Genentech in a different Phase 2 trial Anti-Tau monoclonal antibody was det...
Read More >>Council for Responsible Nutrition welcomed the action against companies that have tarnished consumer confidence for all legitimate products. The U.S. Food and Drug ...
Read More >>The building construction is scheduled to be completed in 2021 and is designed to offer office space, wet labs and a cafeteria. Merck, one of the leaders in the pha...
Read More >>The Torque-Thermo Fisher manufacturing facility is expected to come online by the end of 2019. Thermo Fisher Scientific Inc., the biotechnology products development...
Read More >>The new device possesses the potential to detect specific lung cancer markers at the earliest stage possible. In what may seem to a pathbreaking revolutionary finding i...
Read More >>The generic drug will mean low cost but high-quality drug access to people suffering from chronic respiratory and lung diseases. The U.S. Food and Drug Administrati...
Read More >>The news from Roche marks another failure in developing drugs for Alzheimer’s after many other drugmakers have stopped trials of prospective treatments. Roche...
Read More >>The deal links reimbursement for the blood thinner to the cardiovascular outcomes of patients. Sources familiar with the development ...
Read More >>Purdue Pharma L.P., the Connecticut-based pharmaceutical company, has reportedly announced that it has signed a partnership agreement with Alivio Therapeutics to advance one of its product candidates via clinical devel...
Read More >>U.K. biotech firm Abcam has recently confirmed the acquisition of Calico Biolabs, a specialist in rabbit monoclonal antibodies based out of California. Calico is known to provide custom, high-quality recombinant rabbit...
Read More >>The planned study would assess the efficacy, tolerability, and safety of the derazantinib-atezolizumab combination in patients with confirmed FGFR genomic aberrations and advanced urothelial cancer. ...
Read More >>© 2024 ReportsGO.com. All Rights Reserved.